Physicians' Academy for Cardiovascular Education

Perspectives on the results of recent clinical outcomes trials with EPA

10' education - Oct. 9, 2023 - Gabriel Steg, MD - Paris, France

Video navigation menu

  • Background to REDUCE IT: JELIS 00:41
  • REDUCE IT main results 01:05
  • Safety of icosapent ethyl 02:23
  • REDUCE IT ACS 03:28
  • RESPECT EPA 04:29
  • Contrasting trial results of EPA vs EPA+DHA trials 06:18
  • Conclusions 09:56


Show transcript

Educational information

This lecture by Gabriel Steg, MD was part of the EBAC-accredited symposium "Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl" at the ESC congress 2023.


Gabriel Steg is professor at the Department of Cardiology in the Hôpital Bichat, Paris, France.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Amarin.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: